Ex-Celgene chief Mark Alles, former Goldfinch Bio leader Tony Johnson are back in the game as CEOs
12 Jan 2024
AcquisitionExecutive ChangeIPOADC
→ For the first time since he sold
Celgene
to
Bristol Myers Squibb
for $74 billion in 2019,
Mark Alles
is a CEO again. Alles had been chairing the board at
TORL Biotherapeutics
, an antibody maker from UCLA’s
Dennis Slamon
, and will now pace the sidelines
as CEO of the company
. Since the Celgene buyout, Alles has shown up occasionally in Peer Review by taking board appointments, including
the role of chairman
at
AI Proteins
,
Wugen
and
Turning Point Therapeutics
,
which also caught the eye
of Bristol Myers. Looking to cash in on the antibody-drug conjugate craze, TORL launched last April and
nabbed $158 million in Series B financing
.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.